"Cyclooxygenase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inducibly-expressed subtype of prostaglandin-endoperoxide synthase. It plays an important role in many cellular processes and INFLAMMATION. It is the target of COX2 INHIBITORS.
| Descriptor ID |
D051546
|
| MeSH Number(s) |
D08.811.600.720.750
|
| Concept/Terms |
Cyclooxygenase 2- Cyclooxygenase 2
- Cyclo-Oxygenase II
- Cyclo Oxygenase II
- PTGS2
- PGHS-2
- Prostaglandin H Synthase-2
- Prostaglandin H Synthase 2
- COX-2 Prostaglandin Synthase
- COX 2 Prostaglandin Synthase
- Prostaglandin Synthase, COX-2
- Synthase, COX-2 Prostaglandin
- Cyclooxygenase-2
|
Below are MeSH descriptors whose meaning is more general than "Cyclooxygenase 2".
Below are MeSH descriptors whose meaning is more specific than "Cyclooxygenase 2".
This graph shows the total number of publications written about "Cyclooxygenase 2" by people in this website by year, and whether "Cyclooxygenase 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 5 | 5 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 15 | 15 |
| 2004 | 0 | 8 | 8 |
| 2005 | 2 | 10 | 12 |
| 2006 | 3 | 4 | 7 |
| 2007 | 6 | 4 | 10 |
| 2008 | 5 | 3 | 8 |
| 2009 | 2 | 10 | 12 |
| 2010 | 4 | 7 | 11 |
| 2011 | 3 | 3 | 6 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 4 | 6 |
| 2015 | 3 | 0 | 3 |
| 2016 | 3 | 2 | 5 |
| 2017 | 2 | 0 | 2 |
| 2018 | 0 | 3 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclooxygenase 2" by people in Profiles.
-
Apomorphine is a potent inhibitor of ferroptosis independent of dopaminergic receptors. Sci Rep. 2024 02 27; 14(1):4820.
-
A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-na?ve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms. Neuropsychopharmacology. 2024 Apr; 49(5):893-902.
-
Muscarinic receptor agonist-induced ?Pix binding to ?-catenin promotes colon neoplasia. Sci Rep. 2023 10 07; 13(1):16920.
-
Latest advancements in the study of the relationship between NSAIDs and three prostaglandin E2 synthases. Future Med Chem. 2023 09; 15(17):1549-1552.
-
Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion. Cancer Res Commun. 2023 07; 3(7):1397-1408.
-
Stabilization of E-cadherin adhesions by COX-2/GSK3? signaling is a targetable pathway in metastatic breast cancer. JCI Insight. 2023 03 22; 8(6).
-
Effects of a mildly cooked human-grade dog diet on gene expression, skin and coat health measures, and fecal microbiota of healthy adult dogs. J Anim Sci. 2022 Oct 01; 100(10).
-
Latest progress in the development of cyclooxygenase-2 pathway inhibitors targeting microsomal prostaglandin E2 synthase-1. Future Med Chem. 2022 03; 14(6):385-388.
-
Development of Rofecoxib-Based Fluorescent Probes and Investigations on Their Solvatochromism, AIE Activity, Mechanochromism, and COX-2-Targeted Bioimaging. Anal Chem. 2021 09 07; 93(35):11991-12000.
-
One-Step Transformation from Rofecoxib to a COX-2 NIR Probe for Human Cancer Tissue/Organoid Targeted Bioimaging. ACS Appl Bio Mater. 2021 03 15; 4(3):2723-2731.